Skip to main content

Dana-Farber Research Publication 12.1.2021

View Archive Newsletters

December 1, 2021

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.

Cancer Discovery

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma

Wang T, Wimalasena VK, Zimmerman MW, Li D, Mariani L, Park PMC, Sigua LH, Saur Conway A, Robichaud AL, Perez-Atayde AR, Bulyk ML, Stegmaier K, Look AT, Qi J

Gene expression is regulated by promoters and enhancers marked by histone H3-lysine-27 acetylation (H3K27ac), which is established by the paralogous histone acetyltransferases (HATs), EP300 and CBP. These enzymes display overlapping regulatory roles in untransformed cells, but less characterized roles in cancer cells. We demonstrate that the majority of high-risk pediatric neuroblastoma (NB) depend on EP300, whereas CBP has a limited role. EP300 controls enhancer acetylation by interacting with TFAP2Œ?, a transcription factor member of the lineage-defining transcriptional core regulatory circuitry (CRC) in NB. To disrupt EP300, we developed a proteolysis-targeted-chimaera (PROTAC) compound termed "JQAD1" that selectively targets EP300 for degradation. JQAD1 treatment causes loss of H3K27ac at CRC enhancers and rapid neuroblastoma apoptosis, with limited toxicity to untransformed cells where CBP may compensate. Further, JQAD1 activity is critically determined by cereblon (CRBN) expression across neuroblastoma cells.

Cell Stem Cell

Dietary Suppression of MHC Class II Expression in Intestinal Epithelial Cells Enhances Intestinal Tumorigenesis

Beyaz S, Biton M, Shekhar K, Regev A, Orkin SH, Yilmaz öH

Little is known about how interactions of diet, intestinal stem cells (ISCs), and immune cells affect early-stage intestinal tumorigenesis. We show that a high-fat diet (HFD) reduces the expression of the major histocompatibility complex class II (MHC class II) genes in intestinal epithelial cells, including ISCs. This decline in epithelial MHC class II expression in a HFD correlates with reduced intestinal microbiome diversity. Microbial community transfer experiments suggest that epithelial MHC class II expression is regulated by intestinal flora. Mechanistically, pattern recognition receptor (PRR) and interferon-gamma (IFNŒ?) signaling regulates epithelial MHC class II expression. MHC class II-negative (MHC-II-) ISCs exhibit greater tumor-initiating capacity than their MHC class II-positive (MHC-II+) counterparts upon loss of the tumor suppressor Apc coupled with a HFD, suggesting a role for epithelial MHC class II-mediated immune surveillance in suppressing tumorigenesis. ISC-specific genetic ablation of MHC class II increases tumor burden cell autonomously. Thus, HFD perturbs a microbiome-stem cell-immune cell interaction that contributes to tumor initiation in the intestine.

Journal of Clinical Oncology

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001

Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, Koch V, Kay-Green S, Harris MH, Place AE, Neuberg DS, Sallan SE, Silverman LB

PURPOSE: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL)
Consortium Protocol 11-001 assessed efficacy and toxicity of calaspargase pegol (calaspargase), a novel pegylated asparaginase formulation with longer half-life, compared with the standard formulation pegaspargase.
METHODS: Patients age 1 to 21 years with newly diagnosed ALL or lymphoblastic lymphoma were randomly assigned to intravenous pegaspargase or calaspargase, 2,500 IU/m2/dose. Patients received one induction dose. Beginning week 7, pegaspargase was administered every 2 week for 15 doses and calaspargase every 3 week for 10 doses (30 weeks). Serum asparaginase activity (SAA) (0.1 IU/mL considered therapeutic) was assessed 4, 11, 18, and 25 days after the induction dose and before each postinduction dose.
RESULTS: Between 2012 and 2015, 239 eligible patients enrolled (230 ALL, nine lymphoblastic lymphoma); 120 were assigned to pegaspargase and 119 to calaspargase. After the induction dose, SAA was 0.1 IU/mL in 95% of patients on both arms 18 days after dosing. At day 25, more patients had SAA 0.1 IU/mL with calaspargase (88% v 17%; P ÀÇ .001). Postinduction, median nadir SAAs were similar (1.0 IU/mL) for both arms. Of 230 evaluable patients, 99% of pegaspargase and 95% of calaspargase patients achieved complete remission (P = .12), with no difference in frequency of high end-induction minimal residual disease among evaluable patients with B acute lymphoblastic leukemia (B-ALL). There were no differences in frequencies of asparaginase allergy, pancreatitis, thrombosis, or hyperbilirubinemia. With 5.3 years median follow-up, 5-year event-free survival for pegaspargase was 84.9% (SE 3.4%) and 88.1% (SE 3.0%) for calaspargase (P = .65).
CONCLUSION: Every 3-week calaspargase had similar nadir SAA, toxicity, and survival outcomes compared with every 2-week pegaspargase. The high nadir SAA observed for both preparations suggest dosing strategies can be further optimized.

Journal of Clinical Oncology

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients with Relapsed or Refractory Neuroblastoma: A Report from NANT Consortium

DuBois SG, Shusterman S, Haas-Kogan DA

PURPOSE: 131I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true response rate.
PATIENTS AND METHODS: Patients 1-30 years were eligible if they had relapsed or refractory neuroblastoma, at least one MIBG-avid site, and adequate autologous stem cells. Patients received MIBG 18 mCi/kg on day 1 and autologous stem cell on day 15. Patients randomly assigned to arm A received only MIBG; patients randomly assigned to arm B received intravenous vincristine on day 0 and irinotecan daily on days 0-4; patients randomly assigned to arm C received vorinostat (180 mg/m2/dose) orally once daily on days 1 to 12. The primary end point was response after one course by New Approaches to Neuroblastoma Therapy criteria. The trial was designed with 105 patients to ensure an 80% chance that the arm with highest response rate was selected.
RESULTS: One hundred fourteen patients were enrolled, with three ineligible and six unevaluable, leaving 105 eligible and evaluable patients (36 in arm A, 35 in arm B, and 34 in arm C; 55 boys; and median age 6.5 years). After one course, the response rates (partial response or better) on arms A, B, and C were 14% (95% CI, 5 to 30), 14% (5 to 31), and 32% (18 to 51). An additional five, five, and four patients met New Approaches to Neuroblastoma Therapy Minor Response criteria on arms A, B, and C, respectively. On arms A, B, and C, rates of any grade 3+ nonhematologic toxicity after first course were 19%, 49%, and 35%.
CONCLUSION: Vorinostat and MIBG is likely the arm with the highest true response rate, with manageable toxicity. Vincristine and irinotecan do not appear to improve the response rate to MIBG and are associated with increased toxicity.

Journal of Clinical Oncology

Reply to M. Tanaka et al.

Tolaney SM, Partridge AH, Winer EP, Krop IE

In a letter to the editor in response to our article in Journal of Clinical Oncology,1 Tanaka et al2 bring up several important points. The first concern they raise is the use of a single-arm study design to evaluate invasive disease-free survival (iDFS) with trastuzumab emtansine (T-DM1). While we recognize that ideally a prospective, randomized trial would be conducted, we felt that such a design would not have been feasible if powered to compare efficacy between the two arms. Given the low event rate seen with anti–human epidermal growth factor receptor 2 (HER2) therapy for stage I HER2-positive breast cancer, a randomized trial would require a minimum of several thousands of patients to detect a difference in outcomes. The ATEMPT trial was not designed to replace paclitaxel plus trastuzumab (TH) as the standard of care, but to establish a second treatment option. Our goal was to determine whether treatment with T-DM1 would result in a clinically acceptable iDFS with a 3-year failure rate of 5% or less. Additionally, we sought to compare clinically relevant toxicities (CRTs) between T-DM1 and TH. The trial demonstrated a 3-year iDFS of 97.8%, with just two distant events, and the overall rates of CRTs were similar across the two arms. This trial is not able to conclude that T-DM1 is better than no treatment, nor that treatment with T-DM1 is better than, or equivalent to, treatment with TH. However, given the outstanding efficacy seen with T-DM1, and important patient-reported outcomes suggesting significantly lower rates of neuropathy, better work productivity, and less alopecia, T-DM1 may be considered an alternative treatment option to TH for patients with stage I HER2-positive disease.

Journal of Clinical Oncology

Should Everyone with Ductal Carcinoma in Situ Receive Adjuvant Radiation?

Warren LEG, Bellon JR

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

Journal of the National Cancer Institute

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute

Tolaney SM, Lydon CA, Li T, Dai J, Standring A, Legor KA, Caparrotta CM, Schenker MP, Glazer DI, Tayob N, DuBois SG, Meyerhardt JA, Taplin ME, Johnson BE

Interventions designed to limit the spread of coronavirus disease 2019 (COVID-19) are having profound effects on the delivery of health care, but data showing the impact on oncology clinical trial enrollment, treatment, and monitoring are limited. We prospectively tracked relevant data from oncology clinical trials at Dana-Farber Cancer Institute from January 1, 2018, to June 30, 2020, including the number of open trials, new patient enrollments, in-person and virtual patient visits, dispensed investigational infusions, dispensed or shipped oral investigational agents, research biopsies, and blood samples. We ascertained why patients came off trials and determined on-site clinical research staffing levels. We used 2-sided Wilcoxon rank sum tests to assess the statistical significance of the reported changes. Nearly all patients on interventional treatment trials were maintained, and new enrollments continued at just under one-half the prepandemic rate. The median number of investigational prescriptions shipped to patients increased from 0 to 74 (range = 22-107) per week from March to June 2020. The median number of telemedicine appointments increased from 0 to 107 (range = 33-267) per week from March to June 2020. Research biopsies and blood collections decreased dramatically after Dana-Farber Cancer Institute implemented COVID-19-related policies in March 2020. The number of research nurses and clinical research coordinators on site also decreased after March 2020. Substantial changes were required to safely continue clinical research during the pandemic, yet we observed no increases in serious adverse events or major violations related to drug dosing. Lessons learned from adapting research practices during COVID-19 can inform industry sponsors and governmental agencies to consider altering practices to increase operational efficiency and convenience for patients.


Low Glycaemic Diets Alter Lipid Metabolism to Influence Tumour Growth

Zhang Y, Yuan C, Wolpin BM, Vander Heiden MG

Dietary interventions can change metabolite levels in the tumour microenvironment, which might then affect cancer cell metabolism to alter tumour growth1-5. Although caloric restriction (CR) and a ketogenic diet (KD) are often thought to limit tumour progression by lowering blood glucose and insulin levels6-8, we found that only CR inhibits the growth of select tumour allografts in mice, suggesting that other mechanisms contribute to tumour growth inhibition. A change in nutrient availability observed with CR, but not with KD, is lower lipid levels in the plasma and tumours. Upregulation of stearoyl-CoA desaturase (SCD), which synthesises monounsaturated fatty acids, is required for cancer cells to proliferate in a lipid-depleted environment, and CR also impairs tumour SCD activity to cause an imbalance between unsaturated and saturated fatty acids to slow tumour growth. Enforcing cancer cell SCD expression or raising circulating lipid levels through a higher-fat CR diet confers resistance to the effects of CR. By contrast, although KD also impairs tumour SCD activity, KD-driven increases in lipid availability maintain the unsaturated to saturated fatty acid ratios in tumours, and changing the KD fat composition to increase tumour saturated fatty acid levels cooperates with decreased tumour SCD activity to slow tumour growth. These data suggest that diet-induced mismatches between tumour fatty acid desaturation activity and the availability of specific fatty acid species determine whether low glycaemic diets impair tumour growth.


Publisher Correction: A Metastasis Map of Human Cancer Cell Lines

Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, Deik A, Petronio L, Tang AA, Zhu C, Wang L, Rosenberg D, Roth J, Chung K, Jain RK, Clish CB, Vander Heiden MG, Golub TR

Most deaths from cancer are explained by metastasis, and yet large-scale metastasis research has been impractical owing to the complexity of in vivo models. Here we introduce an in vivo barcoding strategy that is capable of determining the metastatic potential of human cancer cell lines in mouse xenografts at scale. We validated the robustness, scalability and reproducibility of the method and applied it to 500 cell lines1,2 spanning 21 types of solid tumour. We created a first-generation metastasis map (MetMap) that reveals organ-specific patterns of metastasis, enabling these patterns to be associated with clinical and genomic features. We demonstrate the utility of MetMap by investigating the molecular basis of breast cancers capable of metastasizing to the brain-a principal cause of death in patients with this type of cancer. Breast cancers capable of metastasizing to the brain showed evidence of altered lipid metabolism. Perturbation of lipid metabolism in these cells curbed brain metastasis development, suggesting a therapeutic strategy to combat the disease and demonstrating the utility of MetMap as a resource to support metastasis research.

Nature Communications

Fast Alignment and Preprocessing of Chromatin Profiles with Chromap

Song L, Cheng H, Wang C, Meyer CA, Tang M, Aluru S, Liu XS, Li H

As sequencing depth of chromatin studies continually grows deeper for sensitive profiling of regulatory elements or chromatin spatial structures, aligning and preprocessing of these sequencing data have become the bottleneck for analysis. Here we present Chromap, an ultrafast method for aligning and preprocessing high throughput chromatin profiles. Chromap is comparable to BWA-MEM and Bowtie2 in alignment accuracy and is over 10 times faster than traditional workflows on bulk ChIP-seq/Hi-C profiles and than 10x Genomics' CellRanger v2.0.0 pipeline on single-cell ATAC-seq profiles.

Nature Genetics

Esophageal Cancer Mutational Signatures Around the World

Giannakis M

Insofar as cancer is a disease of the genome, mutational signatures hold the promise to divulge its deepest secrets. These patterns of mutations, scattered across the DNA of a cell, have already pointed to the role of endogenous processes and environmental mutagens in the development of several cancer types, but their full potential towards cancer prevention and treatment has yet to be realized. In this issue of Nature Genetics, Moody et al. investigate the mutational patterns in esophageal squamous cell cancer (ESCC) across regions of high and low incidence around the globe4 in a tour-de-force study, exemplifying what is possible through the integration of tumor mutational landscapes with cancer epidemiology.

Nature Immunology

Author Correction: Blockade of IL-22 Signaling Reverses Erythroid Dysfunction in Stress-Induced Anemias

Raundhal M, Ghosh S, Myers SA, Cuoco MS, Singer M, Carr SA, Waikar SS, Bonventre JV, Ritz J, Stone RM, Steensma DP, Regev A, Glimcher LH

Patients with myelodysplastic syndromes (MDSs) display severe anemia but the mechanisms underlying this phenotype are incompletely understood. Right open-reading-frame kinase 2 (RIOK2) encodes a protein kinase located at 5q15, a region frequently lost in patients with MDS del(5q). Here we show that hematopoietic cell-specific haploinsufficient deletion of Riok2 (Riok2f/+Vav1cre) led to reduced erythroid precursor frequency leading to anemia. Proteomic analysis of Riok2f/+Vav1cre erythroid precursors suggested immune system activation, and transcriptomic analysis revealed an increase in p53-dependent interleukin (IL)-22 in Riok2f/+Vav1cre CD4+ T cells (TH22). Further, we discovered that the IL-22 receptor, IL-22RA1, was unexpectedly present on erythroid precursors. Blockade of IL-22 signaling alleviated anemia not only in Riok2f/+Vav1cre mice but also in wild-type mice. Serum concentrations of IL-22 were increased in the subset of patients with del(5q) MDS as well as patients with anemia secondary to chronic kidney disease. This work reveals a possible therapeutic opportunity for reversing many stress-induced anemias by targeting IL-22 signaling.

New England Journal of Medicine

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. Reply.

Choueiri TK

To the Editor: Choueiri et al. (Aug. 19 issue)1 reported a significant improvement in disease-free survival with the addition of adjuvant pembrolizumab after nephrectomy in patients with renal-cell carcinoma (disease-free survival at 24 months, 77.3% vs. 68.1%; hazard ratio, 0.68; 95% confidence interval, 0.53 to 0.87; P=0.002). Although the results are encouraging, the arbitrary duration of 12 months of adjuvant treatment is a concern. In the pembrolizumab group, 61.1% of the patients completed 17 cycles of treatment over 1 year, and the most common reason for treatment discontinuation was an adverse event (which occurred in 21.3% of patients).

Abdominal Radiology

Robustness and Performance of Radiomic Features in Diagnosing Cystic Renal Masses

Könik A, Miskin N, Guo Y, Shinagare AB, Qin L

AJR American Journal of Roentgenology

Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation

Nishino M

American Journal of Clinical Nutrition

Unrestrained Eating Behavior and Risk of Digestive System Cancers: A Prospective Cohort Study

Zhang Y, Song M, Chan AT, Schernhammer ES, Wolpin BM, Stampfer MJ, Meyerhardt JA, Willett WC, Hu FB, Giovannucci EL, Ng K

American Journal of Gastroenterology

Long-Term Statin Use, Total Cholesterol Level, and Risk of Colorectal Cancer: A Prospective Cohort Study

Zhang Y, Wu K, Chan AT, Meyerhardt JA, Giovannucci EL

American Journal of Human Genetics

Allele-Specific Epigenetic Activity in Prostate Cancer and Normal Prostate Tissue Implicates Prostate Cancer Risk Mechanisms

Shetty A, Seo JH, Bell CA, O'Connor EP, Pomerantz MM, Freedman ML, Gusev A

Annals of Surgical Oncology

Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization

Quintana LM, Nimbkar SN, King TA, Schnitt SJ

Behavioral Sleep Medicine

Sleep Education and Training among Practicing Clinical Psychologists in the United States and Canada

Zhou ES

Bioconjugate Chemistry

Direct N- or C-Terminal Protein Labeling Via a Sortase-Mediated Swapping Approach

Cong M, Tavakolpour S, Berland L, Glöckner H, Andreiuk B, Rakhshandehroo T, Uslu S, Mishra S, Clark L, Rashidian M

BJU International

Optimal Pathological Response After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Results from a Global, Multicentre Collaboration

Ravi P, Mossanen M, McGregor BA, Curran C, Sonpavde GP

Blood Advances

Racial and Ethnic Enrollment Disparities and Demographic Reporting Requirements in Acute Leukemia Clinical Trials

Hantel A, Luskin MR, Garcia JS, DeAngelo DJ, Abel GA

Blood Advances

Abatacept for GVHD Prophylaxis Can Reduce Racial Disparities by Abrogating the Impact of Mismatching in Unrelated Donor Stem Cell Transplantation

Duncan C, Kean LS, Horan JT

British Journal of Haematology

Plasmablastic Lymphoma Transformation in a Patient with Waldenström Macroglobulinemia Treated with Ibrutinib

Castillo JJ, LaMacchia J, Flynn CA, Sarosiek S, Pozdnyakova O, Treon SP


Healthy Days at Home: A Population-Based Quality Measure for Cancer Patients at the End of Life

Lam MB, Riley KE, Zheng J, Orav EJ, Burke LG


Spending Outcomes Among Patients with Cancer in Accountable Care Organizations 4 Years After Implementation

Erfani P, Phelan J, Orav EJ, Figueroa JF, Lam MB

Cancer Cytopathology

Precision Medicine in Aggressive Thyroid Cancer: Moving Beyond Multitargeted Tyrosine Kinase Inhibitors

Mahmood U, Lorch JH

Cancer Prevention Research

Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study

Furniss CS, Yurgelun MB, Ukaegbu C, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Rodriguez NJ, Uno H, Garber JE, Syngal S

Cell Reports

Mapping the Evolution of T - cell States During Response and Resistance to Adoptive Cellular Therapy

Bachireddy P, Nguyen VN, Ennis CS, Maurer K, Li S, Gohil SH, Ruthen NG, Keskin DB, Cieri N, Livak KJ, Kim HT, Neuberg DS, Soiffer RJ, Ritz J, Alyea EP, Wu CJ

Clinical Cancer Research

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Regan MM, Jegede OA, Mantia CM, Werner L, Choueiri TK, McDermott DF

Clinical Infectious Diseases

SARS-CoV-2 mRNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity

Sherman AC, Desjardins M, Cheng CA, Bausk B, Izaguirre N, Zhou G, Krauss J, Tolan N, Walt DR, Soiffer R, Ho VT, Issa NC, Baden LR

Clinical Nuclear Medicine

Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination

Hughes NM, Hammer MM, Awad MM, Jacene HA.

Clinical Nutrition

Unrestrained Eating Behavior and Risk of Mortality: A Prospective Cohort Study

Zhang Y, Song M, Yuan C, Chan AT, Schernhammer ES, Wolpin BM, Stampfer MJ, Meyerhardt JA, Rimm EB, Willett WC, Hu FB, Giovannucci EL, Ng K

Current Opinion in Oncology

Maintenance Therapies in Acute Myeloid Leukemia: The Renaissance of an Old Therapeutic Concept

Stahl M

European Journal of Cancer

Current Strategies for Intratumoural Immunotherapy - Beyond Immune Checkpoint Inhibition

Hodi FS

European Journal of Haematology

Post-Transplant Maintenance Therapy in Patients with FLT3-Mutated Acute Myeloid Leukemia: Real-World Treatment Patterns and Outcomes

Griffin JD

European Urology

Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology

Beltran H, Morgans AK

FEBS Journal

In Conversation with Tony Letai

Letai A

Genome Medicine

Constructing Germline Research Cohorts from the Discarded Reads of Clinical Tumor Sequences

Gusev A, Groha S, Semenov YR 

Gynecologic Oncology

Perceived Patient-Centered Communication, Quality of Life, and Symptom Burden in Individuals with Ovarian Cancer

Pozzar RA, Xiong N, Hong F, Wright AA, Underhill-Blazey ML, Tulsky JA, Hammer MJ, Berry DL

Gynecologic Oncology

Distinct Sleep Disturbance Profiles Among Patients with Gynecologic Cancer Receiving Chemotherapy

Pozzar RA, Hammer MJ 


A Prognostic Index Predicting Survival in Transformed Waldenström Macroglobulinemia

Treon SP, Castillo JJ

Human Mutation

SLC25A38 Congenital Sideroblastic Anemia: Phenotypes and Genotypes of 31 Individuals from 24 Families, Including 11 Novel Mutations, and a Review of the Literature

Heeney MM, Berhe S, Campagna DR, Antin JH, Shimamura A, Fleming MD

IEEE Transactions on Radiation and Plasma Medical Sciences

Improved Performance of a Multipinhole SPECT for DAT Imaging by Increasing Number of Pinholes at the Expense of Increased Multiplexing

Könik A 

International Journal of Radiation Oncology, Biology, Physics

Practice Consolidation Among U.S. Radiation Oncologists Over Time

Milligan M, Kim DW, Orav EJ, Figueroa JF, Lam MB

International Journal of Radiation Oncology, Biology, Physics

Dosimetric Planning Tradeoffs to Reduce Heart Dose Using Machine Learning-Guided Decision Support Software in Patients with Lung Cancer

Bitterman DS, Selesnick P, Bredfeldt J, Williams CL, Guthier C, Huynh E, Kozono DE, Cormack RA, Mak RH, Atkins KM


Functional Differences Among the Spike Glycoproteins of Multiple Emerging SARS-CoV-2 Variants of Concern

Wang Q, Anang S, Zhang S, Nguyen H, Sodroski JG

Journal of Geriatric Oncology

Objective Performance Tests of Cognition and Physical Function as Part of a Virtual Geriatric Assessment

Bahl NE, Magnavita ES, Hshieh T, Testa M, Kim D, Manor B, Driver JA, Abel GA, DuMontier C

Journal for Immunotherapy of Cancer

Combining CTLA-4 and Angiopoietin-2 Blockade in Patients with Advanced Melanoma: A Phase I Trial

Ott PA, Nazzaro M, Pfaff KL, Gjini E, Felt KD, Wolff JO, Buchbinder EI, Haq R, Sullivan RJ, Lawrence DP, McDermott DF, Severgnini M, Giobbie-Hurder A, Rodig SJ, Stephen Hodi F

Journal of Managed Care and Specialty Pharmacy

Cost-Effectiveness of a 12-Month Fixed-Duration Venetoclax Treatment in Combination with Obinutuzumab in First-Line, Unfit Chronic Lymphocytic Leukemia in the United States

Davids MS

Journal of Pain and Symptom Management

One Size Doesn't Fit All in Early Pediatric Oncology Bereavement Support

Helton G, Beight L, Morris SE, Wolfe J, Snaman JM

Journal of Palliative Medicine

Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness

Beaussant Y, Tulsky J, Sanders JJ 

Journal of Thoracic Oncology

Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status

Ricciuti B, Lin JJ, Vajdi A, Vokes N, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Gainor JF, Awad MM

JAAD Case Reports

Disseminated Varicella-Zoster Virus Infections Following Messenger RNA-Based COVID-19 Vaccination

Said JT, Virgen CA, Lian CG, Cutler CS, Merola JF, LeBoeuf NR

JAMA Network Open

Association Between Androgen Deprivation Therapy and Mortality Among Patients with Prostate Cancer and COVID-19

Schmidt AL, Bakouny Z, Labaki C, Gao X, Steinharter J, Xu W, Choueiri TK

Lancet Haematology

Indatuximab Ravtansine Plus Dexamethasone with Lenalidomide or Pomalidomide in Relapsed or Refractory Multiple Myeloma: A Multicentre, Phase 1/2a Study

Munshi NC, Anderson KC


A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia

Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR


The Evolving Role of Systemic Therapy and Local, Brain-Directed Treatment in Patients with Melanoma and Brain Metastases

Lamba N, Aizer AA


Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer

Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NU

Pediatric Blood and Cancer

Disparities in Pediatric Psychosocial Oncology Utilization

Zheng DJ, Umaretiya PJ, Schwartz ER, Al-Sayegh H, Ma C, Muriel AC, Bona K

Supportive Care in Cancer

Effect of High-Intensity Interval Training on Patient-Reported Outcomes and Physical Function in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy

Norris MK, Dieli-Conwright CM

Urologic Clinics of North America

Incorporating the Principles of Sex Therapy into Urologic Care

Bober SL